hrp0094p1-1 | Adrenal A | ESPE2021

Optimizing the timing of highest hydrocortisone dose in children and adolescents with 21-hydroxylase deficiency

Schroder Mariska A.M. , van Herwaarden Antonius E. , Span Paul N. , Akker Erica L.T. van den , Bocca Gianni , Hannema Sabine E , Kamp Hetty J. van der , Kort Sandra W.K. de , Mooij Christiaan F. , Schott Dina A. , Straetemans Saartje , Tellingen Vera van , Velden Janielle A. van der , Sweep Fred C.G.J , Claahsen-van der Grinten Hedi L. ,

Context: Children with 21-hydroxylase deficiency (21OHD) require chronic glucocorticoid administration to substitute glucocorticoids and suppress adrenocorticotropic hormone-induced hyperandrogenemia. There is still no evidence about the best timing of the highest hydrocortisone (HC) dose. Administration of the highest dose in the morning aims to mimic the physiological rhythm of cortisol, while a high dose late in the evening may inhibit the early-morning inc...

hrp0094p2-23 | Adrenals and HPA Axis | ESPE2021

Serum cortisol and cortisone, and urinary cortisol, cortisone, and tetrahydro-metabolites concentrations in school-aged children born very preterm adequate for gestational age

Dominguez-Menendez Gonzalo , Ochoa-Molina Maria Fernanda , Poggi Mayorga Helena , Allende Sanzana Fidel , Solari Guajardo Sandra , Fardella Bello Carlos E. , Carvajal Cristian A. , Campino Johnson Carmen , Baudrand Biggs Rene , Garcia Bruce Hernan , Moore Valdes Rosario , D’apremont Ormeno Ivonne , Martinez-Aguayo Alejandro ,

Introduction: Cortisol homeostasis dysregulation has been associated to essential hypertension in adults. Higher levels of cortisol have been described in preterm-born individuals, who have also a higher risk of hypertension at younger ages. Several enzymes modulate peripheric cortisol metabolism. The 11b-hydroxysteroid dehydrogenase (11b-HSD) type 2 metabolizes cortisol into cortisone, preventing mineralocorticoid receptors’ activation by cortisol. The i...

hrp0098rfc7.5 | GH and IGFs | ESPE2024

Health-related quality of life at mid-puberty in adolescents with idiopathic isolated growth hormone deficiency

Vliegenthart Joeri , van Busschbach Jan , Maarten Wit Jan , Bakker Boudewijn , Boot Annemieke , de Bruin Christiaan , Finken Martijn , van der Heyden Josine , Hokken-Koelega Anita , van der Kamp Hetty , de Kort Sandra , van Mil Edgar , Reedijk Ardine , Sas Theo , Schott Nina , van Setten Petra , Straetemans Saartje , van Tellingen Vera , Touwslager Bob , van Trotsenburg Paul , Voorhoeve Paul , van der Kaay Danielle

Introduction: Health related Quality of Life (QoL) outcome is used as an argument when continuation or stopping growth hormone (GH) treatment is considered in patients with idiopathic isolated growth hormone deficiency (IIGHD) who tested GH sufficient in mid-puberty (inclusion moment for this study).Aim: To assess potential differences in QoL between patients with IIGHD who discontinued treatment and those who continued ...

hrp0098p1-116 | Bone, Growth Plate and Mineral Metabolism 2 | ESPE2024

Health related quality of life (HRQoL) of adolescents with XLH treated with burosumab at the end of skeletal growth (EoSG.

Saraff Vrinda , Arango Sancho Pedro , Bacchetta Justine , Linglart Agnès , Burren Christine , Chinoy Amish , Dharmaraj Poonam , Amelia Gómez Llorente Maria , David González Rodríguez Juan , Gueorguieva Iva , Haf Davies Elin , Hayes Wesley , Komarzynski Sandra , Ríos Duro Héctor , J Rylands Angela , Sandilands Kerry , Hardie Emily , Ishii Haruka , Schnabel Dirk , Selveindran San , M Boot Annemieke

Introduction: X-linked hypophosphatemia (XLH) is a rare, progressive, genetic disorder causing phosphate wasting; hence symptoms in children include impaired growth, lower limb deformities, chronic pain and impaired physical function. Health-related quality of life (HRQoL) of patients with XLH on conventional therapy is lower than that of the general population. Burosumab has been shown to improve HRQoL in younger children and adults, but its effects in adoles...

hrp0098p1-90 | Sex Endocrinology and Gonads 1 | ESPE2024

Decreased serum DHEAS to cortisol ratio in adolescents evaluated for gender dysphoria

Tornese Gianluca , Bresciani Giulia , Roia Anna , Sandri Federico , Cosentini Dora , De Zen Lucia , Dalena Paolo , Tamaro Gianluca , Faleschini Elena , Barbi Egidio

Background: DHEAS is the most abundant adrenal steroid and it is also a neurosteroid, produced at the cerebral level from pregnenolone and 17OH-pregnenolone. It antagonizes the effects of cortisol at the level of glucocorticoid receptors, modulating biological energy output, inflammatory status, action of other steroidal hormones, and different brain functions, hypothalamus being rich in corticosteroid receptors. DHEAS secretion is usually synchronized with co...

hrp0092p2-132 | Fat, Metabolism and Obesity | ESPE2019

Association Between TSH and Metabolic Syndrome in Obese Children and Adolescents

Guzzetti Chiara , Ibba Anastasia , Casula Letizia , Casano Simona , Loche Sandro

Introduction: Hyperthyrotropinemia is common in patients with obesity and has been hypothesized that high TSH could be associated with an adverse metabolic profile. Few studies have been performed in pediatric population and the results are controversial.Objective: Aim of the study was to evaluate the association between TSH and metabolic syndrome (MS) in a large group of obese children and adolescents.<p class="abst...

hrp0089p2-p140 | Fat, Metabolism and Obesity P2 | ESPE2018

Sex-related Differences and Effect of Puberty on Metabolic Syndrome in Obese Children and Adolescents

Guzzetti Chiara , Ibba Anastasia , Casula Letizia , Pilia Sabrina , Loche Sandro

Introduction: Metabolic syndrome (MS) is a known complication of obesity. It is still unclear whether gender and puberty influence the prevalence of MS in children and adolescents.Objective: Aim of the study was to evaluate the effect of gender and puberty on the prevalence of MS and on cardiovascular risk factors (CVRF) in obese children and adolescents.Patients and Methods: 1437 obese patients (age 9.7 (2.2–17.9) ys; 660 Mal...

hrp0094p2-456 | Thyroid | ESPE2021

Hashimoto Thyroiditis: long term follow-up from childhood to young adulthood

David Francesco , Casula Letizia , Guzzetti Chiara , Ibba Anastasia , Loche Sandro

Introduction: The evolution of Hashimoto Thyroiditis (HT) has been investigated by several studies both in pediatric and adult age. However, there are limited data on the progression of the disease from childhood to adulthood.Objective: Aim of the study was to describe the evolution of thyroid function in children with HT from childhood to young adulthood.Patients and Methods: The diagnosis of HT was defined by the presence of anti...

hrp0095rfc10.3 | GH and IGFs | ESPE2022

A rare HESX1 variant in a patient with congenital hypopituitarism

Anastasia Ibba , Paraluppi Valentina , Lussu Anna , Guzzetti Chiara , Casula Letizia , Loche Sandro

Background: Congenital hypopituitarism (CH) is characterized by a deficiency of one or more pituitary hormones. Mutations in the genes coding for transcription factors, such HESX1, involved in the development of the pituitary, determine a highly variable phenotype which may include severe midline defects, septo-optic dysplasia and other congenital abnormalities. A small number of HESX1 variants have been identified in humans. The phenotype sh...

hrp0095p1-503 | GH and IGFs | ESPE2022

Adult Height in Patients with Non-Permanent, Idiopathic and Isolated Growth Hormone Deficiency

Guzzetti Chiara , Murianni Agnese , Ibba Anastasia , Casula Letizia , Salerno Mariacarolina , Cappa Marco , Loche Sandro

Background: GH secretion is classically assessed by provocative tests and, indirectly, by IGF-1 serum levels. However, their diagnostic accuracy is low. The aim of the study was to evaluate the adult height (AH) in short patients with IGF-1 ≤-1,5 SDS.Method: 52 short patients (height-SDS -2.6 (-3.1- -2.3), age 12.2 (10.2-13.7) y, 36 boys), with low height velocity(HV)-SDS (-1.6 (-3.2- -0.9)) and IGF-1 ≤-1,5 SDS (-2...